Shimadzu Corp(SHMXY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 11 days
PROFIT SINCE LAST BUY
+1.4% ▲
LAST CLOSE
$14.53
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SHMXY

11/13/2026: SHMXY (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Shimadzu Corporation is a well-established Japanese manufacturer of analytical, medical, and industrial precision instruments. The company benefits from a strong reputation in scientific research and a diversified revenue model that spans global laboratory and clinical healthcare markets. Its primary growth opportunity lies in increasing the automation of complex laboratory workflows and expanding its reach in emerging healthcare markets. However, the company faces significant competitive pressure from larger global peers and potential exposure to currency volatility. It is a stable, long-term focused stock that may best suit value-oriented or conservative investors looking for steady, research-backed industrial exposure, with key developments in clinical diagnostics and R&D spend worth monitoring.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitGrowth is steady and reliable rather than rapid, appealing to those seeking long-term compounders.
Momentum investorWeak fitThe stock tends to follow long-term cycles rather than exhibiting high-frequency momentum signals.
Value investorStrong fitOften trades at valuation levels that value investors find attractive relative to its fundamental quality.
Dividend investorStrong fitProvides a reliable income stream, making it suitable for income-focused portfolios.
Low-risk investorStrong fitThe company's stable business model and long history provide a degree of comfort for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock is subject to currency risks and broader Japanese market fluctuations.
Valuation riskLowCurrent valuations generally reflect stable fundamental performance.
Competition risk (Instrumentation)Medium / highCompetition from larger players like Thermo Fisher can pressure margins.
Business qualityStrongHigh technical barriers to entry support the company's long-term franchise value.
Dividend incomeMediumDividends are reliable but not high-yield compared to specialized income stocks.
Execution riskMediumSuccessful integration of new technology into global markets is critical for growth.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 8.39B USD
Price to earnings Ratio 20.18
1Y Target Price -
Price to earnings Ratio 20.18
1Y Target Price -
Volume (30-day avg) 7.7K shares
Beta 0.74
52 Weeks Range 10.41 - 16.77
Updated Date 11/14/2026
52 Weeks Range 10.41 - 16.77
Updated Date 11/14/2026
Dividends yield (FY) 1.49%
Basic EPS (TTM) 0.72

Sector & Industry Intelligence

Sector

Technology

Caution
Sentiment
Near Bearish
Momentum
Rapid Breadth Deterioration
BUY participation
30.1%
Active BUY / eligible
37 / 123
30-Day BUY Count Change
-42
Market state
Weak Bullish / Near Bearish

BUY participation is falling rapidly, suggesting elevated market vulnerability.

Industry

Scientific & Technical Instruments

BUY participation
0.0%
Active BUY / eligible
0 / 4
30-Day BUY Count Change
-2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -37.82%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SHMXY receives a 3-star rating, supported by solid quantitative characteristics. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
SHMXY has moderate overall fundamentals (3 stars), with solid financial health, solid growth momentum, and moderate ownership. In FY2026 versus FY2025, solid earnings growth (+12.5%) and solid cash generation (FCF margin 7.1%) are partially offset by moderate revenue growth (+4.0%), very low insider ownership of 0.00%.

Financial Health Rating

★★★★★
SHMXY's financial health is supported by strong cash strength, including free-cash-flow generation of $39.7B (7.1% of revenue). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SHMXY's strongest growth driver at +12.5% FY2026 versus FY2025 (solid, 4 stars). Revenue growth (+4.0%, moderate) and free-cash-flow growth (+7.7%, moderate) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 0.0% (soft) and 99.8% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.00%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
SHMXY generates approximately $446 of gross profit, $131 of operating income, and $71 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Moderate margins and soft cash conversion support a 3-star rating, while capital efficiency is moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: 25.73%

Quantitative Style Profile

★★★★★
SHMXY has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Analytical InstrumentsLC-MS, Gas Chromatographs, and other testing equipment for research labs.This is the core profit driver, fueled by ongoing global R&D spending.
Medical SystemsX-ray and diagnostic imaging machines for clinics.Provides a stable, essential healthcare revenue stream.
Geography (Japan)Sales within the domestic Japanese market.A significant revenue base that provides stability but limits geographic diversification.

Valuation

Trailing PE 20.18
Forward PE -
Enterprise Value 8.21B
Price to Sales(TTM) 0.01
Enterprise Value 8.21B
Price to Sales(TTM) 0.01
Enterprise Value to Revenue 2.24
Enterprise Value to EBITDA 11.85
Shares Outstanding 577.63M
Shares Floating 576.28M
Shares Outstanding 577.63M
Shares Floating 576.28M
Percent Insiders -
Percent Institutions -

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.